Stocks Health care EOLS
NASDAQ · Health careEvolus, Inc. (EOLS)
Evolus, Inc. brought in $325.5M of revenue over the twelve months to September 30, 2026, up 13.9% from a year earlier. It posted a net loss of $31.1M. In fiscal 2025 capital spending exceeded operating cash flow by $45.7M. At September 30, 2026 it held $41.7M in cash against $156.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Evolus, Inc.
- Net worth
- Evolus, Inc. has a market value (market cap) of $439.2M at the latest share price, and shareholders' equity of -$37.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $297.2M (+11.6% year on year), with a net loss of $51.6M. Over the 12 months to September 30, 2026: revenue $325.5M, net loss $31.1M.
- Cash flow
- In fiscal 2025 operations used $42.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Evolus, Inc.'s next report is expected around January 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Evolus, Inc. does
Evolus, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker EOLS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $297.2M | -$51.6M | -$0.80 | -$45.7M |
| 2024 | $266.3M | -$50.4M | -$0.81 | -$19.5M |
| 2023 | $202.1M | -$61.7M | -$1.08 | -$34.5M |
| 2022 | $148.6M | -$74.4M | -$1.33 | -$86.5M |
| 2021 | $99.7M | -$46.8M | -$0.94 | -$33.8M |
| 2020 | $56.5M | -$163M | -$4.83 | -$58.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where EOLS ranks in Health care
Latest SEC filings
What Evolus, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Passive stake changed SCHEDULE 13G/A
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 13% to $78M versus the same quarter last year; diluted EPS -$0.19 versus -$0.24.
- November 4, 2026
- August 31, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 21% to $84.1M versus the same quarter last year; diluted EPS -$0.12 versus -$0.27.
- August 5, 2026
- August 4, 2026
- July 8, 2026
- June 12, 2026
- June 5, 2026
Insider trades
What the people running Evolus, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $950K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 2, 2026 | Moatazedi DavidSee Remarks, Director | Sold | 105,108 | $950K |
| March 20, 2026 | Moatazedi DavidSee Remarks, Director | Soldpre-planned (10b5-1) | 13,669 | $64.9K |
| March 20, 2026 | Avelar RuiSee Remarks | Soldpre-planned (10b5-1) | 3,119 | $14.8K |
| March 17, 2026 | Avelar RuiSee Remarks | Soldpre-planned (10b5-1) | 29,996 | $146.6K |
| March 17, 2026 | Moatazedi DavidSee Remarks, Director | Soldpre-planned (10b5-1) | 116,720 | $570.6K |
| March 16, 2026 | Avelar RuiSee Remarks | Exercised options | 8,804 | - |
| March 16, 2026 | Moatazedi DavidSee Remarks, Director | Exercised options | 67,489 | - |
| February 17, 2026 | Gill David NDirector | Received as pay | 45,559 | - |
Who owns EOLS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Timothy P. Lynch13G, passive | 9.9% | February 17, 2026 |
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 8.85% | November 14, 2025 |
| Soleus Capital Master Fund, L.P.13G, passive with 5 related filers | 7.7% | November 9, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 158 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Nantahala Capital Management, LLC | 11,204,042 | +4,827,185 |
| BlackRock, Inc. | 4,840,828 | +550,445 |
| Braidwell LP | 3,155,209 | +50,000 |
| Frazier Life Sciences Management, L.P. | 2,630,665 | 0 |
| Perceptive Advisors LLC | 2,459,285 | +1,172,423 |
| Vanguard Capital Management LLC | 2,362,893 | -107,515 |
| Assenagon Asset Management S.A. | 1,816,360 | +1,218,215 |
| Millennium Management LLC | 1,787,929 | +326,770 |
| State Street Corp | 1,697,294 | +376,504 |
| Geode Capital Management, LLC | 1,608,394 | +227,056 |
| Stonepine Capital Management, LLC | 1,590,162 | -168,929 |
| Point72 Asset Management, L.P. | 1,508,518 | new |
| Pinnacle Associates Ltd | 1,487,264 | +328,369 |
| Armistice Capital, LLC | 1,436,000 | +40,000 |
| Rice Hall James & Associates, LLC | 1,289,888 | +35,069 |
| AWH Capital, L.P. | 1,250,000 | +625,000 |
| Goldman Sachs Group Inc | 1,219,419 | +133,021 |
| Soleus Capital Management, L.P. | 822,428 | -1,422,932 |
| Soviero Asset Management, LP | 770,000 | +89,627 |
| UBS Group AG | 752,679 | -202 |
Insiders
8 insiders reported holding 1,868,970 shares in total, about $12.4M at the last price.
| Holder | Shares |
|---|---|
| Moatazedi DavidSee Remarks, Director | 499,592 |
| Avelar RuiSee Remarks | 427,423 |
| Malik VikramDirector | 321,109 |
| Mitchell TatjanaChief Financial Officer | 226,092 |
| Stewart BradyDirector | 134,188 |
| White Albert G IIIDirector | 95,937 |
| Gill David NDirector | 86,887 |
| Parschauer Karah HerdmanDirector | 77,742 |
Questions about EOLS
What does Evolus, Inc. do?
Evolus, Inc. is a company in the Health care sector, listed on NASDAQ as EOLS. Its shares trade on NASDAQ under the ticker EOLS.
What is Evolus, Inc.'s net worth?
Evolus, Inc. has a market value (market cap) of $439.2M at the latest share price, and shareholders' equity of -$37.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Evolus, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $31.1M on revenue of $325.5M.
How much revenue does Evolus, Inc. make?
Over the twelve months to September 30, 2026 Evolus, Inc. reported revenue of $325.5M. That is 13.9% more than a year earlier.
When did Evolus, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 9, 2026.
When is Evolus, Inc.'s next earnings report?
Evolus, Inc.'s next report is expected around January 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare EOLS with
Follow EOLS
Get an email when Evolus, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Evolus, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.